Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 97 clinical trials
Featured trial
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the safety and antitumor activity of INCB001158 in combination with daratumumab SC, compared with daratumumab SC alone, in participants with relapsed or

refractory multiple myeloma
daratumumab
  • 186 views
  • 10 May, 2022
  • 28 locations
Daratumumab and Belatacept for Desensitization (ATTAIN)

study is to find out whether two drugs, daratumumab (Darzalex®), and belatacept (Nulojix®), can make these kidney transplant candidates less sensitized, and make it easier and quicker to find a kidney

  • 0 views
  • 24 Mar, 2022
  • 1 location
Treatment of POEMS Syndrome With Daratumumab

This trial investigates the use of Daratumumab (DARA), an antibody directed at the human cluster of differentiation 38 (CD38) molecule, for the treatment of patients with Polyneuropathy

  • 4 views
  • 08 Aug, 2021
  • 1 location
SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

Phase 2, single-arm, open, non-randomized, multicenter study of the SINE compound selinexor plus low-dose dexamethasone, in combination with bortezomib and daratumumab. 100 mg selinexor

proteasome inhibitor
monoclonal antibody therapy
growth factor
serum pregnancy test
bortezomib
  • 22 views
  • 05 Mar, 2022
  • 15 locations
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant

This phase II trial studies whether daratumumab and hyaluronidase-fihj and pomalidomide work in treating patients with multiple myeloma that has come back (relapsed) after stem cell transplant

neutrophil count
ejection fraction
daratumumab
tumor cells
growth factor
  • 2 views
  • 03 Feb, 2022
  • 1 location
Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma (CONFIRM)

achieved after first-line therapy. Currently, daratumumab (Dara) is approved by the american FDA and EMA in combination with lenalidomide (Len) and dexamethasone (Dex) or bortezomib and Dex for the

proteasome inhibitor
bortezomib
remission
lenalidomide
azoospermia
  • 0 views
  • 19 Feb, 2022
  • 1 location
Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis

hematologic response and decrease the early death rate. Lately, trials of daratumumab in newly-diagnosed and relapsed/refractory AL amyloidosis have shown dramatic response rates. However, the benefits of

  • 0 views
  • 14 Jun, 2021
  • 1 location
Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction (IDA53)

proliferation and survival. Daratumumab is a first-in-class human IgG1 monoclonal antibody (mAb) that binds CD38-expressing malignant cells with high affinity. Daratumumab induces tumor cell death

  • 2 views
  • 06 Feb, 2022
  • 4 locations
Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma

dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor

cancer
cell transplantation
tumor cells
carbon monoxide
melphalan
  • 0 views
  • 29 Mar, 2021
  • 1 location
Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

daratumumab, dose-attenuated bortezomib, revlimid, and dexamethasone until confirmed disease progression, discontinuation of study treatment due to unacceptable drug toxicity, or other reasons. Throughout the

  • 1 views
  • 16 Feb, 2022
  • 1 location